Insight Lifetech, a China-based heart disease treatment developer backed by medical device provider SiBionics, has received RMB200m ($28.4m) in series B-plus funding, DealStreetAsia has reported.
The round was led by SDIC Gaoxin Industrial Investment, a vehicle of state-owned investment holding group State Development and Investment, and included Green Pine Capital Partners, Efung Capital, Sequoia Capital China, Lotus Lake Capital and Sherpa Venture Partners.
Founded in 2015, Insight Lifetech is developing systems to diagnose and treat coronary heart disease. Its product pipeline includes cardiovascular imaging systems and catheters as well as intravenous ultrasound technology classified as high-priority by Chinese regulators.
The company completed a $14m series B round in 2018 that also featured Sequoia Capital China and Sherpa Venture Partners. Its earlier investors include Sibionics, Decheng Capital and TigerYeah Capital, according to DealStreetAsia.
The original version of this article appeared on our sister site, Global University Venturing.